8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

**Cyclophosphamide**

**Indication**
Lymphoid leukaemia, not elsewhere classified

**ICD11 code:** 2C03.3

**ATC codes:** L01AA01

**Essential medicine status**

**Formulations**
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 2011 (TRS 965)
- Changed in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Cyclophosphamide

**DrugBank**
Cyclophosphamide

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of cyclophosphamide powder for injection (1 g and 2 g) to the EML and EMLc.

[Read more about patents.]